Eli Lilly & Co (LLY) Stock Forecast & Price Target

Compare

16,442 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

17 Buy

1 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,003.60

▲(36.05%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,003.60 with a high forecast of $1,190.00 and a low forecast of $700.00. The average price target represents a 36.05% change from the last price of $737.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"699":"$699","822":"$822","945":"$945","1068":"$1,068","1191":"$1,191"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1003.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$700.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[699,822,945,1068,1191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,792.48,823.0584615384615,853.636923076923,884.2153846153847,914.7938461538462,945.3723076923077,975.9507692307692,1006.5292307692307,1037.1076923076923,1067.686153846154,1098.2646153846154,1128.843076923077,1159.4215384615384,{"y":1190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,792.48,808.72,824.96,841.2,857.44,873.6800000000001,889.9200000000001,906.1600000000001,922.4000000000001,938.6400000000001,954.8800000000001,971.12,987.36,{"y":1003.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,792.48,785.3661538461539,778.2523076923077,771.1384615384616,764.0246153846153,756.9107692307692,749.7969230769231,742.6830769230769,735.5692307692308,728.4553846153847,721.3415384615384,714.2276923076923,707.1138461538461,{"y":700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":770.16,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":814.76,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":908.15,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":826.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":954.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":879.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":814.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":796.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":769.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":808.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":918.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":803.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":792.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,190

Average Price Target$1,004

Lowest Price Target$700.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Nico ChenDBS

DBS

$1,010

Buy

36.92%

Upside

Reiterated

05/30/25

Eli Lilly's Strong Market Position and Innovative Drug Pipeline Justify Buy Rating with Target Price of USD 1,010

Trung HuynhUBS

UBS

$1,050

Buy

42.34%

Upside

Reiterated

05/29/25

UBS Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Geoff MeachamCiti

Citi

$1,190

Buy

61.32%

Upside

Reiterated

05/28/25

Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Evan SeigermanBMO Capital

BMO Capital

$900

Buy

22.01%

Upside

Assigned

05/27/25

Eli Lilly's Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating

Seamus FernandezGuggenheim

Guggenheim

$928→$936

Buy

26.89%

Upside

Reiterated

05/23/25

Eli Lilly (LLY) PT Raised to $936 at GuggenheimGuggenheim analyst Seamus Fernandez raised the price target on Eli Lilly (NYSE: LLY) to $936.00 (from $928.00) while maintaining a Buy rating.

Tim AndersonBank of America Securities

Bank of America Securities

$1,000

Buy

35.56%

Upside

Assigned

05/22/25

Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities

Terence FlynnMorgan Stanley

Morgan Stanley

$1,133

Buy

53.59%

Upside

Reiterated

05/22/25

Morgan Stanley weighs in on Eli Lilly (LLY) following Cigna GLP-1 newsMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY) after Cigna/Evernorth recently announced a new benefit option capping patient copays at $200 per month on both Lillys Zepbound and Novos Wegovy and maintaining its less exclusionary approach.

Courtney BreenBernstein

Bernstein

$1,100

Buy

49.12%

Upside

Reiterated

05/19/25

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Terns Pharmaceuticals (TERN)

Mohit BansalWells Fargo

Wells Fargo

$1,100

Buy

49.12%

Upside

Reiterated

05/14/25

Analysts Conflicted on These Healthcare Names: Kezar Life Sciences (NASDAQ: KZR), Eli Lilly & Co (NYSE: LLY) and Becton Dickinson (NYSE: BDX)

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/12/25

Eli Lilly's Zepbound Outperforms Competitors in Weight Loss Trials, Supporting Buy Recommendation

Umer RaffatEvercore ISI

Evercore ISI

―

Hold

―

Reiterated

05/12/25

Eli Lilly & Co (LLY) Gets a Hold from Evercore ISI

Akash TewariJefferies

Jefferies

$1,020→$1,057

Buy

43.29%

Upside

Reiterated

05/02/25

Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges

Asad HaiderGoldman Sachs

Goldman Sachs

$888→$883

Buy

19.70%

Upside

Reiterated

05/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Moderna (NASDAQ: MRNA) and Envista Holdings (NYSE: NVST)

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/02/25

Truist Financial Remains a Buy on Eli Lilly & Co (LLY)

Steve ScalaTD Cowen

TD Cowen

$1,050

Buy

42.34%

Upside

Reiterated

05/01/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Nico ChenDBS

DBS

$1,010

Buy

36.92%

Upside

Reiterated

05/30/25

Eli Lilly's Strong Market Position and Innovative Drug Pipeline Justify Buy Rating with Target Price of USD 1,010

Trung HuynhUBS

UBS

$1,050

Buy

42.34%

Upside

Reiterated

05/29/25

UBS Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Geoff MeachamCiti

Citi

$1,190

Buy

61.32%

Upside

Reiterated

05/28/25

Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Evan SeigermanBMO Capital

BMO Capital

$900

Buy

22.01%

Upside

Assigned

05/27/25

Eli Lilly's Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating

Seamus FernandezGuggenheim

Guggenheim

$928→$936

Buy

26.89%

Upside

Reiterated

05/23/25

Eli Lilly (LLY) PT Raised to $936 at GuggenheimGuggenheim analyst Seamus Fernandez raised the price target on Eli Lilly (NYSE: LLY) to $936.00 (from $928.00) while maintaining a Buy rating.

Tim AndersonBank of America Securities

Bank of America Securities

$1,000

Buy

35.56%

Upside

Assigned

05/22/25

Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities

Terence FlynnMorgan Stanley

Morgan Stanley

$1,133

Buy

53.59%

Upside

Reiterated

05/22/25

Courtney BreenBernstein

Bernstein

$1,100

Buy

49.12%

Upside

Reiterated

05/19/25

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Terns Pharmaceuticals (TERN)

Mohit BansalWells Fargo

Wells Fargo

$1,100

Buy

49.12%

Upside

Reiterated

05/14/25

Analysts Conflicted on These Healthcare Names: Kezar Life Sciences (NASDAQ: KZR), Eli Lilly & Co (NYSE: LLY) and Becton Dickinson (NYSE: BDX)

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/12/25

Eli Lilly's Zepbound Outperforms Competitors in Weight Loss Trials, Supporting Buy Recommendation

Umer RaffatEvercore ISI

Evercore ISI

―

Hold

―

Reiterated

05/12/25

Eli Lilly & Co (LLY) Gets a Hold from Evercore ISI

Akash TewariJefferies

Jefferies

$1,020→$1,057

Buy

43.29%

Upside

Reiterated

05/02/25

Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges

Asad HaiderGoldman Sachs

Goldman Sachs

$888→$883

Buy

19.70%

Upside

Reiterated

05/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Moderna (NASDAQ: MRNA) and Envista Holdings (NYSE: NVST)

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/02/25

Truist Financial Remains a Buy on Eli Lilly & Co (LLY)

Steve ScalaTD Cowen

TD Cowen

$1,050

Buy

42.34%

Upside

Reiterated

05/01/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

28/38 ratings generated profit

Average Return

+4.76%

assigned a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.68% of your transactions generating a profit, with an average return of +4.76% per trade.

3 Months

xxx

Success Rate

28/38 ratings generated profit

Average Return

+9.27%

assigned a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +9.27% per trade.

1 Year

Chris SchottJ.P. Morgan

Success Rate

30/37 ratings generated profit

Average Return

+34.09%

reiterated a buy rating last month

Copying Chris Schott's trades and holding each position for 1 Year would result in 81.08% of your transactions generating a profit, with an average return of +34.09% per trade.

2 Years

xxx

Success Rate

25/30 ratings generated profit

Average Return

+29.64%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +29.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 62 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,003.60.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $5.54 with a range of $5.19 to $6.00. The previous quarter’s EPS was $3.34. LLY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year LLY has Outperformed its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $14.34B with a range of $13.96B to $14.80B. The previous quarter’s sales results were $12.73B. LLY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year LLY has Outperformed its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,003.60.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 36.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 1 sell ratings.

What is Eli Lilly & Co’s price target?

The average price target for Eli Lilly & Co is 1,003.60. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,190.00 ,the lowest forecast is $700.00. The average price target represents 36.05% Increase from the current price of $737.67.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts